About
Chris Hollowood is the Chief Executive Officer of Syncona Investment Management Limited, the investment manager of Syncona, a UK life-sciences investment firm. He has been with Syncona since its 2012 launch, previously serving as Chief Investment Officer, and has led the development of its gene therapy strategy across ocular, hepatic, renal, and CNS therapeutics. He previously was a partner at Apposite Capital LLP and currently holds board roles across several Syncona portfolio companies including Spur, Beacon, Yellowstone, and Purespring.
Areas of interest
life sciencesbiotechgene therapyimmuno-oncologycell therapyophthalmologyrenal diseaseoncologycardiovascular therapeuticsdrug discovery